This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pohost, G. M. Search for Related Content PubMed PubMed Citation Articles by Pohost, G. M.

(Circulation. 1995;92:9-10.)
© 1995 American Heart Association, Inc.

Articles

Is ³¹P-NMR Spectroscopic Imaging a Viable Approach to Assess Myocardial Viability?

Gerald M. Pohost, MD

From the Division of Cardiovascular Disease, the Center for Nuclear Magnetic Resonance Research and Development, and the Department of Radiology, University of Alabama at Birmingham.

Correspondence to Dr Pohost, 311-THT, UAB Station, Birmingham, AL 35294-0006.

Key Words: Editorials • spectroscopy • imaging

	Introduction

 
Thallium-201 imaging in its various forms (initial followed by 2- to 4-hour or 24-hour delayed imaging, initial followed by imaging after reinjection, or a "hybrid" approach using ²⁰¹Tl initially and ^99mTc-sestamibi later) is a reasonable clinical approach for assessment of myocardial perfusion and viability.^{1 2 3 4} However, other approaches that examine change in regional myocardial function during dobutamine infusion and evaluate metabolic myocardial integrity with exogenous administration of radioactive tracers also have been reported.^{5 6 7} Accordingly, one may justifiably wonder how nuclear magnetic resonance (NMR) spectroscopic imaging, another expensive, high-tech approach, might ever be used as a clinical tool for assessing myocardial viability, especially in this era of healthcare reform, managed care, and capitation.

Yabe et al⁸ report a new clinical approach for evaluating myocardial viability. The method uses ³¹P-NMR spectroscopic imaging (SI) to quantify the high-energy phosphates ATP and phosphocreatine (PCr). The use of ATP concentration as a standard for assessing myocardial viability is not new.⁹ What is new is the ability to estimate ATP and PCr concentrations clinically and noninvasively in asynergic segments of myocardium.

Wall motion abnormalities associated with ischemic heart disease may be related to myocardial scar in patients with previous myocardial infarction, an irreversible situation, or to transient ischemic dysfunction ("stunning")¹⁰ or persistent ischemic dysfunction ("hibernation").¹¹ Reversible or irreversible dysfunction can suggest the appropriate therapeutic strategy. With viable but dysfunctional myocardium, bypass graft surgery or catheterization laboratory intervention can lead to improved function and symptomatic state of the patient—or even extension of longevity. With nonviable myocardium, there is . . . [Full Text of this Article]

This article has been cited by other articles:

				M. Saeed New Concepts in Characterization of Ischemically Injured Myocardium by MRI Experimental Biology and Medicine, May 1, 2001; 226(5): 367 - 376. [Abstract] [Full Text]

				P. A. Bottomley and R. G. Weiss Noninvasive Localized MR Quantification of Creatine Kinase Metabolites in Normal and Infarcted Canine Myocardium Radiology, May 1, 2001; 219(2): 411 - 418. [Abstract] [Full Text]

				G. M. Pohost and R. W. W. Biederman The Role of Cardiac MRI Stress Testing : "Make a Better Mouse Trap ... " Circulation, October 19, 1999; 100(16): 1676 - 1679. [Full Text] [PDF]